Aggrenox End-Payors Reach $54M Deal In Pay-For-Delay Suit
A proposed class of indirect Aggrenox buyers told a Connecticut federal judge on Monday that they have reached a $54 million settlement agreement with Teva Pharmaceutical and Boehringer Ingelheim over allegations...To view the full article, register now.
Already a subscriber? Click here to view full article